Fig. 3From: Overweight with HBV infection limited the efficacy of TACE in hepatocellular carcinoma by inhibiting the upregulated HMGB1The overall PFS and OS curves show the PFS and OS of all patients reviewed. Group1 = Normal weight HCC patients without HBV infection; Group2 = Normal weight HCC patients combined HBV infection; Group3 = Overweight HCC patients without HBV infection; Group4 = Overweight HCC patients combined HBV infection; PFS = progression-free survival; OS = overall survivalBack to article page